Zacks Research Analysts Reduce Earnings Estimates for ACAD

Key Points

• Zacks Research has lowered its Q2 2025 earnings per share (EPS) estimate for ACADIA Pharmaceuticals from $0.14 to $0.13.
• The company reported $0.11 EPS for the last quarter, exceeding analysts' estimates of $0.10 EPS, alongside an 18.7% year-over-year revenue increase.
• Several analysts have upgraded their ratings on ACADIA Pharmaceuticals with price targets such as $35.00 from Deutsche Bank and $37.00 from JMP Securities.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Equities researchers at Zacks Research decreased their Q2 2025 earnings per share estimates for shares of ACADIA Pharmaceuticals in a report released on Tuesday, July 29th. Zacks Research analyst A. Chakraborty now expects that the biopharmaceutical company will earn $0.13 per share for the quarter, down from their previous forecast of $0.14. The consensus estimate for ACADIA Pharmaceuticals' current full-year earnings is $0.70 per share. Zacks Research also issued estimates for ACADIA Pharmaceuticals' Q3 2025 earnings at $0.13 EPS, Q4 2025 earnings at $0.11 EPS, FY2025 earnings at $0.48 EPS, Q2 2026 earnings at $0.18 EPS, Q4 2026 earnings at $0.20 EPS, FY2026 earnings at $0.77 EPS, Q2 2027 earnings at $0.25 EPS and FY2027 earnings at $1.05 EPS.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last issued its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.11 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.10 by $0.01. ACADIA Pharmaceuticals had a return on equity of 17.46% and a net margin of 22.97%. The business had revenue of $244.32 million during the quarter, compared to the consensus estimate of $239.32 million. During the same period last year, the company earned $0.10 EPS. The company's revenue for the quarter was up 18.7% on a year-over-year basis.

Other analysts also recently issued reports about the company. Deutsche Bank Aktiengesellschaft raised ACADIA Pharmaceuticals from a "hold" rating to a "buy" rating and raised their target price for the stock from $20.00 to $35.00 in a research note on Wednesday, May 21st. Robert W. Baird raised their target price on ACADIA Pharmaceuticals from $28.00 to $31.00 and gave the stock an "outperform" rating in a research note on Monday, May 19th. Royal Bank Of Canada increased their price target on ACADIA Pharmaceuticals from $26.00 to $38.00 and gave the stock an "outperform" rating in a report on Monday, June 23rd. Mizuho raised their target price on ACADIA Pharmaceuticals from $20.00 to $23.00 and gave the company a "neutral" rating in a report on Monday, May 19th. Finally, BMO Capital Markets lifted their price objective on ACADIA Pharmaceuticals from $24.00 to $28.00 and gave the company an "outperform" rating in a research note on Monday, May 19th. Six investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $28.13.

ACADIA Pharmaceuticals Stock Down 1.3%

Shares of ACAD traded down $0.30 during midday trading on Wednesday, reaching $23.53. The company had a trading volume of 1,750,031 shares, compared to its average volume of 1,634,986. ACADIA Pharmaceuticals has a 1-year low of $13.40 and a 1-year high of $25.23. The stock has a market cap of $3.94 billion, a PE ratio of 17.18, a price-to-earnings-growth ratio of 6.54 and a beta of 0.70. The firm has a 50 day simple moving average of $22.18 and a 200-day simple moving average of $19.05.

Insiders Place Their Bets

In other ACADIA Pharmaceuticals news, EVP Mark C. Schneyer sold 2,000 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Friday, May 16th. The stock was sold at an average price of $25.00, for a total transaction of $50,000.00. Following the transaction, the executive vice president owned 62,130 shares of the company's stock, valued at $1,553,250. The trade was a 3.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Laura Brege sold 14,446 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Wednesday, June 4th. The stock was sold at an average price of $21.78, for a total value of $314,633.88. Following the transaction, the director directly owned 15,095 shares in the company, valued at approximately $328,769.10. This trade represents a 48.90% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 20,446 shares of company stock valued at $454,634 over the last quarter. Company insiders own 26.50% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Exchange Traded Concepts LLC purchased a new stake in shares of ACADIA Pharmaceuticals in the first quarter valued at approximately $29,000. Picton Mahoney Asset Management purchased a new stake in shares of ACADIA Pharmaceuticals in the first quarter valued at approximately $32,000. Banque Transatlantique SA purchased a new stake in shares of ACADIA Pharmaceuticals in the first quarter valued at approximately $31,000. Virtus Fund Advisers LLC purchased a new stake in shares of ACADIA Pharmaceuticals in the fourth quarter valued at approximately $39,000. Finally, Federated Hermes Inc. boosted its stake in shares of ACADIA Pharmaceuticals by 231.5% in the first quarter. Federated Hermes Inc. now owns 2,317 shares of the biopharmaceutical company's stock valued at $38,000 after buying an additional 1,618 shares in the last quarter. 96.71% of the stock is currently owned by hedge funds and other institutional investors.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.